Harvard Stem Cell Institute (HSCI) scientists at Massachusetts General Hospital led by Dr Khalid Shah, who hails from Kashmir, experimented on mice and used genetically engineered stem cells that released cancer-killing toxins while leaving healthy cells unaffected.
The modified cells, most importantly, were able to release the tumour killing poison without succumbing to its effects.
"A few years ago, we recognised that stem cells could be used to continuously deliver these therapeutic toxins to tumours in the brain, but first we needed to genetically engineer stem cells that could resist being killed themselves by the toxins," Shah an HSCI Principal Faculty member said.
During the tests, the main brain tumour was surgically removed before the stem cells were placed at the site of the tumour in a biodegradable gel to eradicate the remaining cancerous cells.
"Cancer-killing toxins have been used with great success in a variety of blood cancers, but they don't work as well in solid tumours because the cancers aren't as accessible," added Shah.
The work, considered a breakthrough in cancer treatment by experts, has been published in the Stem Cells journal.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
